Phase II multicenter clinical trial of hypoallergenic 1BS-18 Hokushin bread oral immunotherapy for wheat-dependent exercise-induced anaphylaxis
Approximately 80% of patients with WDEIA were able to safely consume 1BS-18 Hokushin bread at least up to 60 g per day for 12 weeks without severe adverse reactions. However, this regimen did not achieve desensitization, suggesting that further studies may be necessary to explore alternative dosing, duration, or combinations with adjunct therapies for effective desensitization in patients with WDEIA.
Authors
- Ritsuro Suzuki (ORCID: https://orcid.org/0000-0002-5974-7614)
- M. Okamoto (ORCID: https://orcid.org/0000-0002-3880-8414)
- Michihiro Hide (ORCID: https://orcid.org/0000-0002-1569-6034)
- Atsushi Fukunaga (ORCID: https://orcid.org/0000-0003-2026-8154)
- Kunie Kohno (ORCID: https://orcid.org/0000-0003-0935-7092)
- Yoshiko Oda (ORCID: https://orcid.org/0000-0002-5244-0871)
- Yuko Chinuki
- Eishin Morita (ORCID: https://orcid.org/0000-0002-5427-8468)
- Reiko Kishikawa
- Akiko Sugiyama (ORCID: https://orcid.org/0000-0001-8550-3536)
Institutions
- Hiroshima University (JP)
- Shimane University (JP)
- National Hospital Organization (JP)
- Shimane University Hospital (JP)
- Kobe University (JP)
- Osaka University of Pharmaceutical Sciences (JP)
Publication Details
- Journal
- Asia Pacific Allergy
- Published
- 2025-02-05
- DOI
- https://doi.org/10.5415/apallergy.0000000000000180
- Citations
- 1
- Primary Topic
- Food Allergy and Anaphylaxis Research
- Type
- article
- Field-Weighted Citation Impact
- 1.62
Funders
- Lotte Foundation
- Japan Society for the Promotion of Science